HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use

Executive Summary

CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.

You may also be interested in...

EU Regulators Clarify Rules On Nasal Spray Claims Ahead Of Cold & Flu Season

The EU's medical device regulators have joined forces to remind consumer health firms of the rules which must be followed when marketing a nasal spray offering protection from viruses, such as influenza and SARS-CoV-2.

US OTC Switch For Cialis At Top Of To-Do List For Sanofi’s North American Consumer Health Chief

Andrew Loucks moves to Sanofi from helm of consumer health and technology firm Sensory Cloud as business navigates gaining US OTC heartburn market share for Zantac brand, which it relaunched with famotidine replacing ranitidine as the active ingredient.

COVID-19 False Advertising Wasn't Any Falser Than During Other Public Health Crises; The Internet Was The Difference Maker

The types of unsupported claims made during the COVID-19 pandemic have not been so different from those seen before when the US faced public health emergencies. But this time advertisers' digital capabilities turned up the volume on false and unsubstantiated claims about COVID cures and the like, says Rich Cleland, FTC Consumer Protection Bureau attorney.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts